The impact of Charlson Comorbidity Index on survival outcomes in men with prostate cancer who underwent definitive prostate radiotherapy

Document Type

Conference Proceeding

Publication Date

2019

Publication Title

J Clin Oncol

Abstract

Background: Life expectancy is very essential in deciding treatment options in men with prostate cancer (PCa); however, the impact of comorbidities on outcomes is not well-established. We investigated the influence of Charlson Comorbidity Index (CCI) on survival endpoints in men with localized PCa who were treated with prostate radiotherapy (RT). Methods: Men with intermediate and high risk PCa who were treated with definitive RT between 1/2007 and 12/2012 were included. Groups were created according to their baseline CCI score at diagnosis into no, mild and severe comorbidity (CCI 0, 1 or 2+). The groups were then compared based on patients' characteristics and prognostic factors. Kaplan-Meier curves and Uni/multivariate analyses (MVA) were used to examine the impact of CCI groups on overall (OS), disease specific (DSS), and biochemical relapse free (BRFS) survival. Results: 257 patients were identified after excluding low risk, metastatic cases and those with inadequate follow up. Median follow-up was 92 months (range: 21-35) and median age was 73 years (range: 4885). 53% of the cases were black and 67% were of intermediate risk. Median RT dose was 76 Gy and 47% received androgen deprivation therapy. CCI groups 0, 1 and 2+ encompassed 76 (30%), 54 (21%) and 127 (49%) patients, respectively. Groups were generally wellbalanced. 10 and 15 years OS was significantly different across CCI groups (76% & 53%, 46% & 31% and 55% & 14%, for CCI-0, 1 and 2+ respectively; p < 0.001). CCI-0 had better DSS than CCI2+ (p = 0.03) with no difference for CCI-0 vs 1 (p = 0.1). BRFS was nondifferent among CCI groups (p = 0.99). On MVA, increased CCI was deterministic for OS (p < 0.001) after adjusting for age, Gleason's score and T-stage. For DSS, only age and T3 vs T1/2 were independently prognostic (p < 0.001); whereas CCI1 vs 0 was only marginal (p = 0.05). Conclusions: Higher CCI was a significant predictor of shorter OS in intermediate and high-risk PCa. Baseline comorbiditiesshould be taken into consideration during patient counselling for treatment options and in designing prospective trials for men with localized prostate cancer.

Volume

37

Issue

7 Suppl

First Page

114

This document is currently not available here.

Share

COinS